Last mentioned: Feb 20, 2026
A wave of earnings reports and clinical trial results has triggered significant volatility across the healthcare and biotech sectors. While Genmab reported a decline in full-year profits, breakthrough Phase 3 results from Compass Pathways and Ocular Therapeutix highlight a sharp divergence between clinical success and market valuation.
Genmab A/S reported a decline in full-year profits, marking a period of significant financial and clinical divergence across the biotechnology sector. While breakthrough results in depression therapy propelled Compass Pathways, Ocular Therapeutix suffered a sharp decline despite meeting Phase 3 trial endpoints.
A wave of fourth-quarter earnings reports reveals a bifurcated landscape for retail-adjacent sectors, with hardware supplier Hillman Solutions facing a stock sell-off despite sales growth while consumer health giant Kenvue sees profit gains. Meanwhile, retail real estate remains a bright spot as major REITs like RioCan and Vicinity Centres report income growth, signaling resilient physical commerce demand.